Sofinnova Partners
Sofinnova Partners is a Paris-headquartered European life-sciences venture capital firm founded in 1972, managing €4B+ across seven specialized strategies from seed to later-stage biotech, medtech, and sustainability, having backed 500+ companies.
- Company typePrivate
- Founded1972
- HeadquartersParis, France
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Sofinnova Partners does
Sofinnova Partners is a privately held European venture capital firm founded in 1972 and headquartered in Paris that invests exclusively across the life-sciences value chain, from seed to later-stage. The firm operates seven dedicated investment strategies — Capital (flagship early-stage biotech/medtech), MD Start (in-house medtech accelerator), Crossover (late-stage clinical biotech/medtech), Industrial Biotech (sustainability), Telethon (Italian rare genetic diseases), Digital Medicine (techbio/AI), and Biovelocita (biotech accelerator) — collectively managing over €4 billion in assets and having backed more than 500 companies. Offices in Paris, London, and Milan support investment activity across Europe and the United States.
Sofinnova positions itself as a "company creator" rather than a pure financier, frequently incubating and spinning out companies before founders appear (e.g., MD Start, Biovelocita, Noema Pharma, Bionyra Pharma). At the center of operations is Sofia, a proprietary AI platform trained on 50+ years of internal investment data and deployed on AWS infrastructure; Sofia supports scientific and clinical analysis, market mapping, pitch deck analysis, competitive landscape reports, partnership/licensing insights, and a KOL/executive ranking tool, with a founder-facing version launched through a June 2026 AWS collaboration. The firm is AMF-registered since 1997 and AIFM-authorized since 2014, managing professional FPCI, SLP, and RAIF vehicles, and is GDPR- and SFDR-compliant.
Revenue is generated through three streams: recurring management fees on seven AIFM-authorized fund vehicles; carried interest from successful exits including Actelion→Johnson & Johnson, CoreValve→Medtronic, Shockwave Medical→Johnson & Johnson, Mablink→Eli Lilly, Corvidia→Novo Nordisk, and GlycoVaxyn→GlaxoSmithKline; and long-duration strategic capital from Apollo, which took a minority equity stake in May 2022 alongside an up-to-€1 billion commitment to Sofinnova's investment funds. The firm has raised successive flagship vintages from Capital VI (€260M, 2008) through Capital XI (€650M, 2025), and remains independent and Paris-based.
Sofinnova Partners firmographics
Firmographics- Name
- Sofinnova Partners
- Legal name
- Sofinnova Partners SAS
- Website
- https://sofinnovapartners.com
- Company type
- Private
- Founded year
- 1972
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Sofinnova Partners is a Paris-headquartered European life-sciences venture capital firm founded in 1972, managing €4B+ across seven specialized strategies from seed to later-stage biotech, medtech, and sustainability, having backed 500+ companies.
- Ownership category
- akta.pro rank
Sofinnova Partners industry classification
Industry- Product category
- Venture Capital — Life Sciences
- NAICS
- Portfolio Management and Investment Advice (52394)
- SIC
- Security Brokers, Dealers & Flotation Companies (6211)
- akta.pro primary industry
- Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)
Keywords
Where Sofinnova Partners is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices3 records
Markets served
Sofinnova Partners business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others
Revenue model
- Fund Management Fees: As an AMF-registered portfolio management company (AIFM authorized since July 2014), Sofinnova earns recurring management fees on its seven investment strategies and their AUM (€4 billion+), which include flagship Capital funds, MD Start, Crossover, Industrial Biotech, Telethon, Digital Medicine, and Biovelocita vehicles.
- Carried Interest (Performance Fees) on Funds: Carried interest earned from successful exits and realizations across 500+ portfolio companies including Actelion (J&J), ProQR, CoreValve (Medtronic), Shockwave Medical (J&J), Recor Medical (Otsuka), Mablink (Eli Lilly), Corvidia (Novo Nordisk), GlycoVaxyn (GSK), and Omthera (AstraZeneca).
- Strategic Capital from Apollo Partnership: Up to €1 billion commitment from Apollo to Sofinnova's investment funds, with Apollo taking a minority equity stake — providing long-duration capital to accelerate fund growth.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Professional fund vehicles (FPCI, SLP, RAIF) with management fees and carried interest — only available to qualified investors |
| Other | Multi-year contract | Equity financing to portfolio companies via seed, Series A, Series B+, and crossover rounds |
Go-to-market motion4 records
Sofinnova Partners product offering
Product offeringCore offering
Sofinnova Partners is a venture capital firm that provides equity financing to life-sciences startups from seed through later-stage across seven dedicated investment strategies: Capital (flagship early-stage biopharma and medtech), MD Start (medtech accelerator), Crossover (late-stage clinical biotech/medtech), Industrial Biotech (sustainability), Telethon (Italian rare-disease science), Digital Medicine (techbio/healthtech), and Biovelocita (biotech accelerator). The firm also operates Sofia, a proprietary AI platform built on AWS that supports deal sourcing, scientific and clinical analysis, market mapping, expert ranking, and competitive landscape analysis, with a founder-facing version extended to portfolio startups.
Product overview
Sofinnova Partners operates a multi-fund platform of investment strategies with dedicated specialist teams, rather than a single unified software product. At the center of the firm's operations is Sofia, the proprietary AI platform that supports investing and company building across all strategies by analyzing scientific, clinical, and market data, ranking experts and entrepreneurs, and providing competitive landscape, asset benchmarking, and partnership/licensing insights to founders. The platform is built on more than 50 years of internal Sofinnova data and is being extended through a collaboration with AWS into a founder-facing version for portfolio companies. Around Sofia, the firm offers seven dedicated investment strategies: Sofinnova Capital (flagship early-stage biopharma/medtech), Sofinnova MD Start (medtech accelerator), Sofinnova Crossover (late-stage clinical-stage biotech/medtech), Sofinnova Industrial Biotech (sustainability and industrial biotech), Sofinnova Telethon (Italian rare genetic disease investments), Sofinnova Digital Medicine (techbio and healthtech at the intersection of biology, data, and computation), and Sofinnova Biovelocita (biotech accelerator with European research organizations). Together, Sofia and the seven strategies form an integrated life-sciences investment platform that supports founders from seed to later-stage commercialization across healthcare and sustainability.
Differentiator
Problem solved
Functional benefit
Brands
- Sofia: Sofinnova's proprietary AI platform, developed to support investing and company building in life sciences, with tools for scientific and clinical analysis, market mapping, and pitch deck analysis. Extended in 2026 through an AWS collaboration to include a founder-facing version.
- BiovelocITA
Products and services
- Sofinnova Capital Strategy Flagship investment strategy providing equity financing as founding or lead investor in early-stage biopharma and medtech startups developing groundbreaking therapeutic technologies across Europe and the United States. Most recent vintage, Capital XI, closed at €650 million in November 2025 with plans to back 50-60 companies.
- Sofinnova MD Start Strategy In-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building, turning identified clinical needs into ground-breaking medical devices. Combines direct management, financial support, and access to Sofinnova's infrastructure and network.
- Sofinnova Crossover Strategy Late-stage investment strategy that invests in clinical-stage biotech and medtech companies (both public and private) whose innovations have initial proof of concept, supporting portfolio companies as they achieve clinical milestones and scale toward commercial readiness.
- Sofinnova Industrial Biotech Strategy Environmental impact strategy backing early-stage sustainable companies applying biotechnology to the agriculture, food, chemicals, and materials sectors.
- Sofinnova Telethon Strategy Strategy making early-stage investments in leading Italian science for the benefit of patients with rare genetic diseases, in partnership with the Telethon Foundation. Supported by InnovFin Equity under EU Horizon 2020 and EFSI.
- Sofinnova Digital Medicine Strategy Strategy backing early-stage startups innovating at the intersection of biology, data, and computation, working with founders to build companies leveraging AI, machine learning, and data analytics to transform healthcare.
- Sofinnova Biovelocita Strategy In-house biotech accelerator partnering with Europe's leading research organizations to create and accelerate European biotech start-ups, providing a hands-on, structured framework for company creation built on direct management, financial support, and Sofinnova's infrastructure and network.
- Sofia AI Platform Sofinnova's proprietary AI platform that supports investing and company building in life sciences, bringing together tools for scientific and clinical analysis, market mapping, and pitch deck analysis into a single system, powered by more than 50 years of internal data. Being extended to a founder-facing version built on AWS to give portfolio startups access to AI-driven competitive landscape, asset benchmarking, and partnership/licensing tools.
Companies that use Sofinnova Partners
Customer profileNamed customers29 records
Ideal customer profiles3 records
Sofinnova Partners technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability8 records
Feature4 records
Sofinnova Partners partnerships and signals
Strategic signalScale indicators11 records
Recent moves9 records
Expansion highlights6 records
Sofinnova Partners competitors and assessment
Company assessmentDirect peers
- Abingworth: Abingworth is a transatlantic life sciences investment firm with venture and crossover strategies, comparable to Sofinnova's combination of Capital and Crossover. Joe Anderson, now at Sofinnova, previously co-founded Arix and was a partner at Abingworth.
- Omega Funds: Omega Funds is a Boston-based healthcare and life sciences investment firm active across private and public biotech, comparable to Sofinnova's Crossover strategy. It is an ELSC co-founder.
- HealthCap: HealthCap is a Nordic-European life sciences VC firm investing from seed through late-stage biotech and medtech. It is an ELSC co-founder and a directly comparable peer across stages and therapeutic areas.
- Forbion: Forbion is a leading European life sciences VC firm managing multiple funds across biotech and medtech. It is the most direct European peer to Sofinnova's Capital, Crossover, and Biovelocita strategies, and a fellow ELSC co-founder.
- EQT Life Sciences (formerly LSP): EQT Life Sciences is a European healthcare VC platform investing across early and growth stages in biotech and medtech. It is a direct peer to Sofinnova's Capital and Crossover strategies and an existing co-investor (e.g., Neurent Medical).
- Atlas Venture: Atlas Venture is a US/European biotech-focused early-stage VC firm building companies from inception, directly comparable to Sofinnova's Capital and MD Start company-creation model.
- Novo Holdings (Novo Seeds / Novo Ventures): Novo Holdings operates early-stage (Novo Seeds) and later-stage (Novo Ventures) life sciences funds, directly competing for European biotech deals. It is also an ELSC co-founder and a co-investor alongside Sofinnova in deals like Hemab.
- M Ventures: M Ventures is the strategic corporate venture arm of Merck KGaA, investing in life sciences including biotech, medtech, and digital health across stages. It is comparable to Sofinnova's multi-strategy approach, particularly in Industrial Biotech and Digital Medicine.
- Ysios Capital: Ysios Capital is a Spain-based life sciences VC firm investing in early- and late-stage European biotech. It is closely comparable in strategy and stage focus to Sofinnova Capital and is an established co-investor in European biotech rounds.
Others
- Apollo Global Management (Healthcare): Apollo is a strategic LP and minority equity holder in Sofinnova, and a broader healthcare investor. It is an ecosystem participant rather than a direct competitor, but materially shapes Sofinnova's capital base and growth trajectory.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Sofinnova Partners social profiles
Digital presenceSofinnova Partners compliance and trust
Trust signalCompliance4 records
Sofinnova Partners financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sofinnova Partners leadership team
Management profileNumber of profiles
Profiles9 records
Sofinnova Partners subsidiaries and ownership
Company hierarchySubsidiaries2 records
Sofinnova Partners funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sofinnova Partners M&A and investment
M&A and investmentM&A
Investments382 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sofinnova Partners
What does Sofinnova Partners do?
Sofinnova Partners is a venture capital firm that provides equity financing to life-sciences startups from seed through later-stage across seven dedicated investment strategies: Capital (flagship early-stage biopharma and medtech), MD Start (medtech accelerator), Crossover (late-stage clinical biotech/medtech), Industrial Biotech (sustainability), Telethon (Italian rare-disease science), Digital Medicine (techbio/healthtech), and Biovelocita (biotech accelerator). The firm also operates Sofia, a proprietary AI platform built on AWS that supports deal sourcing, scientific and clinical analysis, market mapping, expert ranking, and competitive landscape analysis, with a founder-facing version extended to portfolio startups.
Is Sofinnova Partners a public or private company?
Sofinnova Partners is a private company. It is classified as private equity controlled and is currently operating.
When was Sofinnova Partners founded?
Sofinnova Partners was founded in 1972. It employs 51 to 100 people.
Where is Sofinnova Partners based?
Sofinnova Partners is headquartered in Paris, France, in the Europe region.
How does Sofinnova Partners make money?
Three revenue lines are on record. Fund Management Fees are the primary driver. The others are carried Interest (Performance Fees) on Funds and strategic Capital from Apollo Partnership.
Who are Sofinnova Partners's main competitors?
Direct peers on record are Abingworth, Omega Funds, HealthCap, Forbion, EQT Life Sciences (formerly LSP), Atlas Venture, Novo Holdings (Novo Seeds / Novo Ventures), M Ventures and Ysios Capital. Apollo Global Management (Healthcare) is listed as an others.
Does Sofinnova Partners have an API?
No public API is recorded for Sofinnova Partners.
What industry is Sofinnova Partners in?
Sofinnova Partners's product category is Venture Capital — Life Sciences. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 52394 and its SIC code is 6211.